UltraGreen.ai Shows Strong Pricing Power Growth with 23% Profit Rise, Maintains Buy Rating at US$1.91 Target August 21, 2026

UltraGreen.ai Shows Strong Pricing Power Growth with 23% Profit Rise, Maintains Buy Rating at US$1.91 Target

Company Overview

UltraGreen.ai operates in the fluorescence guided imaging sector, specialising in ICG vials and imaging equipment including the IC-Flow camera system. The company serves global markets across the Americas, EMEA, and APAC regions, with regulatory approvals for its Verdye product and IC-Flow camera across multiple countries.


Strong Financial Performance Drives Growth

UltraGreen.ai demonstrated robust financial results in 1H26, with adjusted revenue and PATMI rising 30.7% and 23.4% year-on-year to US$87.2 million and US$39.5 million respectively. These figures represent 47% and 44% of full-year forecasts, indicating solid progress towards annual targets.

The performance was primarily driven by the full-half impact of US vial average selling price increases implemented in 3Q25, combined with higher global vial volumes. The Americas region, which accounts for 75% of total revenue, experienced a significant 22% year-on-year increase in average selling price to US$173 per vial. This pricing power demonstrates the company’s strong market position and ability to pass through price adjustments effectively.


Volume Growth Across International Markets

Beyond pricing improvements, UltraGreen.ai achieved impressive volume growth, with global vial sales increasing 11% year-on-year to 589,511 vials. International expansion proved particularly successful, with ICG vial volumes in EMEA and APAC regions growing 24% and 45% respectively. This growth was supported by expanded regulatory approvals, with Verdye now approved in 43 countries compared to 35 previously, and the IC-Flow camera approved in 46 countries versus 40 previously.

The company’s profitability was further enhanced by higher interest income of US$2.47 million, representing approximately a 37-fold increase year-on-year, as management deployed cash reserves into interest-bearing instruments.


Investment Outlook and Catalysts

Phillip Securities Research maintains a Buy recommendation with a target price of US$1.91, slightly reduced from the previous US$1.92. The minor adjustment reflects higher administrative expenses related to increased headcount and employee share ownership plan costs, resulting in 5% reductions to FY26e and FY27e profit forecasts.

UltraGreen.ai currently trades at a FY26e price-to-earnings ratio of 16.4x. Key catalysts for future performance include progress on PerfusionWorks’ US FDA approval process and the strategic deployment of unspent IPO proceeds towards mergers and acquisitions and other capital initiatives.


Frequently Asked Questions

Q: What drove UltraGreen.ai's strong 1H26 performance?

A: The company's revenue and profit growth was primarily driven by US vial price increases implemented in 3Q25 that provided a full-half impact in 1H26, combined with higher global vial volumes and increased interest income from deploying cash into interest-bearing instruments.

Q: How much did vial prices increase in key markets?

A: The Americas region, which represents 75% of total revenue, experienced a 22% year-on-year increase in average selling price to US$173 per vial.

Q: What was the volume growth performance across different regions?

A: Global vial volumes increased 11% year-on-year to 589,511 vials, with particularly strong growth in international markets where EMEA volumes rose 24% and APAC volumes increased 45%.

Q: What is Phillip Securities Research's recommendation and target price?

A: Phillip Securities Research maintains a Buy recommendation with a target price of US$1.91, slightly reduced from the previous US$1.92 target.

Q: How did regulatory approvals contribute to growth?

A: New country approvals supported volume growth, with Verdye now approved in 43 countries (up from 35) and the IC-Flow camera approved in 46 countries (up from 40).

Q: What are the key catalysts investors should watch?

A: Key catalysts include progress on PerfusionWorks' US FDA approval process and the deployment of unspent IPO proceeds towards mergers and acquisitions and other capital initiatives.

Q: At what valuation is UltraGreen.ai currently trading?

A: The company is trading at a FY26e price-to-earnings ratio of 16.4x.

Q: Why was the target price reduced slightly?

A: The target price was lowered marginally to account for higher administrative expenses related to larger headcount and employee share ownership plan expenses, resulting in 5% reductions to FY26e and FY27e profit forecasts.

UltraGreen.ai Shows Strong Pricing Power Growth with 23% Profit Rise, Maintains Buy Rating at US$1.91 Target

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.

 

Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

About the author

Hashim Osman

Hashim graduated from the National University of Singapore with a degree in Business Administration.

Related Articles

Ever Glory United Holdings Ltd – Order Book Surges Past S$1bn Ever Glory United Holdings Ltd – Order Book Surges Past S$1bn
Singapore REITs Monthly – Strong DPU Growth in 1H26 Singapore REITs Monthly – Strong DPU Growth in 1H26
17LIVE Group Limited – Coverage Ceasing as Company Pursues Diversification Strategy 17LIVE Group Limited – Coverage Ceasing as Company Pursues Diversification Strategy
BRC Asia Ltd – PATMI accelerates, balance sheet strengthens BRC Asia Ltd – PATMI accelerates, balance sheet strengthens
Market Journal

Join Events & Seminars

Learn best practices and latest market outlook from experts and special guests

Market Journal

Hear & Ask our Experts

Join live weekly market calls

Market Journal

Read Popular News & Reports, Technical Pulses

at www.poems.com.sg/stock-research

Market Journal

Subscribe to our YouTube Channel

New video every week

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com